ACTRN12608000546358已完成不适用
Phase III-B, open randomized study to evaluate the coronary vasodilator effect of a generic or reference propatylnitrate formulation administrated in sublingual route during coronariography
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •subject who was clinical indicated to investigate coronary disease;
- •subject who had not used a nitrate formulation or a calcium channel antagonist 12 hours before coronariography
排除标准
- •Acute miocardial infarction in less than 7 days; uncontrolled heart failure; cardiogenic arrest or haemodinamics instability; left coronary branch lesion >50%, non protected; left ventricular ejection fraction <30%; previous diagnosis of anterior decendent artery or cincurnflex occlusion; previous angioplasty with or without stent on the proximal third of the anterior decendent artery or on the circunflex; renal failure with creatinine >1,8mg/dl or patient dojng peritoneal dyalises or hemodyalisis
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity & safety study of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine 208136Measles, mumps, rubella and varicella diseasesEUCTR2011-004485-15-Outside-EU/EEAGlaxoSmithKline Biologicals474
进行中（未招募）
3 期
Immunogenicity and safety study of two different formulations of GlaxoSmithKline (GSK) Biologicalsâ?? oral live attenuated human rotavirus (HRV) vaccine, Rotarix in healthy infants.CTRI/2014/06/004654GlaxoSmithKline Biologicals450
进行中（未招募）
1 期
A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) in healthy female subjects aged 20 to 25 years - HPV-026 PRICervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.EUCTR2007-007876-41-BEGlaxoSmithKline Biologicals
进行中（未招募）
不适用
A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up immunization in children older than 7 months of age or given as a 3-dose primary immunization in children before 6 months of age. - 10PN-PD-DIT-013Catch-up immunization against Streptococcus pneumoniae in children older than 7 months at the time of the first vaccination and subdivided according to the age:•7 to 11 months of age.•12 to 23 months of age.•24 months to 5 years of age.EUCTR2006-001482-42-FIGlaxoSmithKline Biologicals600
进行中（未招募）
不适用
A phase IIIb, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant booster administration of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine with GSK Biologicals’ Infanrix hexa vaccine in children at 12-15 months of age following a 3-dose primary vaccination in study 10PN-PD-DIT-010 (107017) and to evaluate the impact of pneumococcal vaccination on nasopharyngeal carriage compared to a pneumococcal vaccine unprimed control group receiving GSK iologicals' meningococcal serogroup ACWY conjugate vaccine. - 10PN-PD-DIT-014 BST:010EUCTR2006-001481-17-CZGlaxoSmithKline Biologicals860